Valuation : Ocugen, Inc.

Market Cap 448M 385M 361M 331M 617M 42.31B 622M 4.28B 1.67B 21.62B 1.68B 1.64B 69.64B P/E 2026 *
-5.08x
P/E 2027 * -4.71x
Enterprise Value 448M 385M 361M 331M 617M 42.31B 622M 4.28B 1.67B 21.62B 1.68B 1.64B 69.64B EV / Sales 2026 *
94.1x
EV / Sales 2027 * 179x
Free-Float
98.28%
Yield 2026 *
-
Yield 2027 * -
1 day+1.14%
1 week-1.46%
Current month+1.50%
1 month+8.00%
3 months+3.85%
6 months-27.42%
1 week 1.28
Extreme 1.28
1.38
1 month 1.21
Extreme 1.21
1.49
Current year 1.16
Extreme 1.16
2.72
1 year 1.01
Extreme 1.01
2.72
3 years 0.34
Extreme 0.345
2.72
5 years 0.34
Extreme 0.345
17.65
10 years 0.17
Extreme 0.17
18.77
Manager TitleAgeSince
Chief Executive Officer 62 27/09/2019
Director of Finance/CFO - 09/02/2026
Chief Operating Officer - 01/03/2026
Director TitleAgeSince
Chairman 62 27/09/2019
Director/Board Member 59 01/09/2013
Director/Board Member 59 01/09/2019
Date Insider Type Main position Quantity % Market Cap. Importance
01/04/26 Exercice

Director

388,268 0.1184%
04/03/26 Other

Chief Financial Officer

1,250,350 0.3813%
02/01/26 Free

Chief Executive Officer

6,246,402 2.0000%
Change 5-day change 1-year change 3-year change Capi.($)
+2.27%-1.46%+28.57%+198.67% 448M
-0.24%-0.99%+3.26%+18.17% 50.14B
+0.78%-4.65%+430.22%+525.91% 44.85B
+2.95%+3.52%+47.12%+22.97% 43.43B
+0.25%-2.63%+7.86%+77.06% 41.14B
+0.43%-3.26%+14.75%+49.08% 32.92B
+1.43%+8.73% - - 17.56B
+0.06%-2.97%+23.31%+123.84% 16.55B
+0.93%+0.88%+19.64%+29.70% 14.65B
+0.54%-1.03%+80.71%+43.59% 13.93B
Average +0.88%-1.33%+72.83%+121.00% 27.56B
Weighted average by Cap. +0.89%-1.14%+93.48%+129.67%

Financials

2026 *2027 *
Net sales 4.76M 4.09M 3.84M 3.51M 6.56M 450M 6.61M 45.44M 17.7M 230M 17.86M 17.47M 740M 2.5M 2.15M 2.02M 1.85M 3.45M 236M 3.47M 23.88M 9.3M 121M 9.39M 9.18M 389M
Net income -87.21M -75.03M -70.41M -64.42M -120M -8.24B -121M -833M -324M -4.21B -327M -320M -13.57B -97.94M -84.26M -79.08M -72.35M -135M -9.26B -136M -935M -364M -4.73B -368M -360M -15.24B
Net Debt - -
Logo Ocugen, Inc.
Ocugen, Inc. is a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines that improve health and offer hope for patients across the globe. Its technology pipeline includes Novel Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, and Inhaled Mucosal Vaccine Platform. It is developing its modifier gene therapy platform, inclusive of OCU400, OCU410, and OCU410ST, for the treatment of multiple inherited retinal diseases, including retinitis pigmentosa, Stargardt disease and multifactorial diseases, such as dry age-related macular degeneration (dAMD) and geographic atrophy. It is developing a next-generation, inhalation-based mucosal vaccine platform based on a novel ChAd vector, which includes OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine, and OCU520, a combination quadrivalent seasonal flu.
Employees
116
Date Price Change Volume
04/09/26 $1.350 +2.27% 2,388,129
02/09/26 $1.320 -0.75% 4,284,876
01/09/26 $1.330 0.00% 2,180,897
31/08/26 $1.330 +0.76% 4,663,343
28/08/26 $1.320 -3.65% 3,100,322
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
1.320USD
Average target price
12.17USD
Spread / Average Target
+821.72%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. OCGN Stock